rhu-pgelsolin
Recombinant proteinexperimental
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2008 (NCT00671307)
Timeline
Indications
Studied for
Mechanism of action
- GelsolinSupplementation
GSN supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- NCATSJBT6SFF5BV ↗
- ChEMBLCHEMBL6068622 ↗
Also known as
- rhu-pgelsolin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06216366 | Phase 2 | Jan 15, 2025 | BioAegis Therapeutics Inc. |
| NCT05947955 | Phase 2 | Apr 1, 2024 | BioAegis Therapeutics Inc. |
| NCT05789745 | Phase 1 | Mar 14, 2023 | BioAegis Therapeutics Inc. |
| NCT04358406 | Phase 2 | Jun 30, 2020 | BioAegis Therapeutics Inc. |
| NCT03466073 | Phase 1/Phase 2 (Phase 2) | Aug 3, 2018 | BioAegis Therapeutics Inc. |
| NCT00671307 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2008 | Critical Biologics Corporation, The University of Hong Kong |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BioAegis Therapeutics Inc. | For profit | 5 | 5 | 2 | 2018 |
| Critical Biologics Corporation | For profit | 1 | 1 | 1 | 2008 |
| The University of Hong Kong | Academic/Hospital | 1 | 0 | 1 | 2008 |
3 organizations
Page 1 / 1